Valuation: Profound Medical Corp.

Market Cap 336M 242M 209M 196M 179M 23.12B 342M 2.3B 902M 11.6B 908M 889M 38.6B P/E 2026 *
-8.14x
P/E 2027 * -11.9x
Enterprise Value 336M 242M 209M 196M 179M 23.12B 342M 2.3B 902M 11.6B 908M 889M 38.6B EV / Sales 2026 *
9.28x
EV / Sales 2027 * 5.65x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day+6.09%
1 week-4.31%
Current month-5.97%
1 month+1.67%
3 months+2.63%
6 months+6.90%
Current year-9.38%
1 week 9.03
Extreme 9.03
9.91
1 month 9.03
Extreme 9.03
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.69
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 14/08/2016
Director of Finance/CFO - 13/08/2026
President 44 06/11/2024
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 13/06/2018
Director/Board Member 79 13/06/2018
Date Insider Type Main position Quantity % Market Cap.
24/06/26 Option

Director

2,016 0.0055%
17/06/26 Option

Chairperson

11,618 0.0320%
24/12/25 Buy

Executive/Senior Manager

13,908 0.0461%
Change 5-day change 1-year change 3-year change Capi.($)
+6.09%-4.31%+63.76%-18.67% 242M
+0.60%-1.78%+20.46%+9.90% 216B
-1.51%-4.68%-5.38%-21.06% 142B
+0.22%-0.56%-18.55%+34.85% 138B
-1.87%+0.02%-51.08%-0.92% 74.53B
+0.19%-1.14%+16.25%+18.42% 52.34B
+1.18%+0.74%-16.17%-14.38% 50.28B
-0.01%-0.19%+24.53%+22.83% 41.93B
-1.59%-2.55%+37.63%+46.89% 40.06B
+0.36%-0.43%-1.05%+6.20% 32.69B
Average +0.37%-1.45%+7.04%+8.41% 78.89B
Weighted average by Cap. -0.22%-1.17%-0.19%+9.07%

Financials

2026 *2027 *
Net sales 36.22M 26.05M 22.52M 21.17M 19.27M 2.49B 36.81M 248M 97.22M 1.25B 97.88M 95.74M 4.16B 59.46M 42.76M 36.97M 34.75M 31.63M 4.09B 60.43M 408M 160M 2.05B 161M 157M 6.83B
Net income -44.08M -31.7M -27.41M -25.76M -23.45M -3.03B -44.8M -302M -118M -1.52B -119M -117M -5.06B -31.27M -22.49M -19.44M -18.27M -16.63M -2.15B -31.78M -214M -83.93M -1.08B -84.5M -82.65M -3.59B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
18/08/26 CA$9.760 +6.09% 10,634
17/08/26 CA$9.200 0.00% 16,288
14/08/26 CA$9.200 -1.71% 7,381
13/08/26 CA$9.360 -3.70% 15,732
12/08/26 CA$9.720 -0.21% 26,130
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.200
Average target price
-

Quarterly revenue - Rate of surprise